This article is more than 5 years old. Information may no longer be current.

Entyvio safely treats immunotherapy-induced enterocolitis

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

PHILADELPHIA – Treatment with Entyvio for immunotherapy-induced enterocolitis demonstrated favorable outcomes and a good safety profile, according to data presented at the American College of Gastroenterology Annual Meeting.

“Immunotherapy is a treatment for a vast number of malignancies with great success in achieving response,” Hamzah Abu-Sbeih, MD, from the University of Texas MD Anderson Cancer Center, said during his presentation. “However, it is common for immunotherapy success to be limited by adverse events with enterocolitis being among the more common outcomes. Therefore, we sought an alternative effective treatment for immunotherapy-induced enterocolitis.”

The retrospective, multi-center study comprised 28 patients with immune mediated diarrhea and colitis (IMDC) who received Entyvio (vedolizumab, Takeda Pharmaceuticals) from December 2016 to 2018. All patients had IMDC that was refractory to steroids or infliximab therapy.

During a median follow-up of 15 months, the patients underwent between one and four 300 mg infusions of vedolizumab with most patients receiving three infusions.

Twenty-four patients achieved sustained clinical remission for a rate of 86%. After repeat endoscopic evaluation in 17 patients, the researchers found seven of 13 patients who had abnormal endoscopic findings attained endoscopic remission. Of those seven, five also reached histological remission.

One patient developed a skin rash and one patient had joint pain for an adverse event rate of 8%.

“Vedolizumab is an effective alternative treatment for enterocolitis that is refractory to steroids. However, the study is limited by the sample size and retrospective nature,” Abu-Sbeih said. “Therefore, prospective studies are warranted to validate our findings.” – by Talitha Bennett

Reference : Abu-Sbeih H. Abstract 61. Presented at: American College of Gastroenterology Annual Scientific Meeting; Oct. 5-10, 2018; Philadelphia.

Disclosure: Abu-Sbeih reports no relevant financial disclosures.